# IceCure Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement
Canonical URL: https://biopharmsignal.com/news/ICCM/icecure-granted-180-day-extension-by-nasdaq-to-regain-compliance-with-minimum-bid-requirement
Ticker: ICCM
Company: IceCure Medical
Source: IceCure Medical
Published: 2026-05-13 20:30 EST
Original Source URL: https://ir.icecure-medical.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-07-14 12:32 EST — [IceCure Expands U.S. Commercial Team to Meet Surging Demand for ProSense® Cryoablation](https://biopharmsignal.com/news/ICCM/icecure-expands-u-s-commercial-team-to-meet-surging-demand-for-prosense-cryoabla-7980c317) — Source: IceCure Medical
- 2026-07-06 12:11 EST — [IceCure Highlights Expanding Commercial Adoption of ProSense™ Cryoablation in Brazil Following FDA Clearance for Breast Cancer](https://biopharmsignal.com/news/ICCM/icecure-highlights-expanding-commercial-adoption-of-prosense-cryoablation-in-bra-814ddba1) — Source: IceCure Medical
- 2026-06-25 12:12 EST — [IceCure Regains Compliance with Nasdaq Minimum Bid Price Requirement](https://biopharmsignal.com/news/ICCM/icecure-regains-compliance-with-nasdaq-minimum-bid-price-requirement-7340e049) — Source: IceCure Medical
- 2026-06-23 12:10 EST — [IceCure Highlights New Peer-Reviewed Journal Article in Leading Surgery Journal, Demonstrating Cryoablation's Advantages Over Radiofrequency Ablation for Early-Stage Breast Cancer](https://biopharmsignal.com/news/ICCM/icecure-highlights-new-peer-reviewed-journal-article-in-leading-surgery-journal--2af39cdd) — Source: IceCure Medical
- 2026-06-17 17:14 EST — [IceCure Announces Pricing of $5.5 Million Private Placement Priced At a Premium to the Market Price with a Single Healthcare Focused Institutional Investor](https://biopharmsignal.com/news/ICCM/icecure-announces-pricing-of-5-5-million-private-placement-priced-at-a-premium-t-b922b2c5) — Source: IceCure Medical
## Related News
- 2026-07-21 20:15 EST — BFRG — [BullFrog AI to Participate in Water Tower Research Fireside Chat on Thursday, July 23, 2026](https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-water-tower-research-fireside-chat-on-thursday-jul-78357ce8)
- 2026-07-21 20:05 EST — CLPT — [ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026](https://biopharmsignal.com/news/CLPT/clearpoint-neuro-to-announce-second-quarter-2026-results-august-3-2026-6e4f3c05)
- 2026-07-21 20:05 EST — TCMD — [Tactile Medical to Release Second Quarter of Fiscal Year 2026 Financial Results on August 10, 2026](https://biopharmsignal.com/news/TCMD/tactile-medical-to-release-second-quarter-of-fiscal-year-2026-financial-results--798d4004)
- 2026-07-21 20:05 EST — PIII — [P3 Health Partners Schedules Second Quarter 2026 Earnings Release and Conference Call](https://biopharmsignal.com/news/PIII/p3-health-partners-schedules-second-quarter-2026-earnings-release-and-conference-6c9bd8a7)
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)